Navigation Links
Inverseon's Asthma Therapy Receives Notice of Allowance; Clinical Trial Highlighted in Lancet
Date:1/14/2009

eve," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events, or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

    Contact:
    William J. Garner, MD
    bill@inverseon.com
   http://www.inverseon.com
    (415) 440-7400

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Inverseon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
2. Visualizing asthma-causing immune cells at work
3. New consensus on work-related asthma
4. Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11
5. New Patient Satisfaction Study With budesonide/formoterol Combination Therapy and fluticasone/salmeterol Combination Therapy in Adults With Asthma
6. Asthma Uncontrolled in More Than 40 Percent of Adults With the Disease, New Landmark Survey Shows
7. Asthma Patients Not Adequately Controlled on ICS Alone More Likely to Benefit From Advair(R) Than Doubling the Dose of ICS
8. Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management
9. Allergy Standards LTD to Attend 2008 American Academy of Allergy, Asthma and Immunology Conference
10. FDA Grants Market Clearance to Aerocrine Inc.s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma
11. Drug Reduces Airway Mucus in Preclinical Asthma Model
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Einstein receives high-risk/high-reward cancer research funding 2Einstein receives high-risk/high-reward cancer research funding 3Stem cells battle for space 2How to read brain activity? 2MEDA Receives FDA Approval of New ASTEPRO 28R 29 28azelastine HCl 29 Nasal Spray 0 15 25 the First and Only Once Daily Nasal Antihistamine 55998 1MEDA Receives FDA Approval of New ASTEPRO 28R 29 28azelastine HCl 29 Nasal Spray 0 15 25 the First and Only Once Daily Nasal Antihistamine 55998 2MEDA Receives FDA Approval of New ASTEPRO 28R 29 28azelastine HCl 29 Nasal Spray 0 15 25 the First and Only Once Daily Nasal Antihistamine 55998 3MEDA Receives FDA Approval of New ASTEPRO 28R 29 28azelastine HCl 29 Nasal Spray 0 15 25 the First and Only Once Daily Nasal Antihistamine 55998 4MEDA Receives FDA Approval of New ASTEPRO 28R 29 28azelastine HCl 29 Nasal Spray 0 15 25 the First and Only Once Daily Nasal Antihistamine 55998 5Providence Service Corporation to Present at the Baird 2009 Healthcare Conference on September 9 55994 1Providence Service Corporation to Present at the Baird 2009 Healthcare Conference on September 9 55994 2Derma Sciences To Present at Rodman 26 Renshaws Eleventh Annual Healthcare Conference 55990 1Derma Sciences To Present at Rodman 26 Renshaws Eleventh Annual Healthcare Conference 55990 2Derma Sciences To Present at Rodman 26 Renshaws Eleventh Annual Healthcare Conference 55990 3